Abivax race — the field (scorecard attached), a rising price tag, and why AZN can’t be ruled out
Following on the AZN read-across: Soriot’s FT interview lays out the exact demand backdrop — “nearly $20bn of sales” going generic after 2030 and only “halfway to a target of launching 20 new medicines by 2030” — that keeps AstraZeneca in the frame for a de-risked immunology asset. But AZN is the outsider here, not the favourite, and the price to play just went up. I’ve put the full buyer field in the attached one-page scorecard (strategic fit vs. ability to fund a ~$20bn+ take-out, ranked most-to-least likely).
The likely buyer field (detail in the attached scorecard).
Abivax has been a named takeover target since JPM in January, when Eli Lilly was reported to be eyeing a ~€15bn ($17.5bn) deal. The tension across the field is that the best strategic fits and the deepest pockets aren’t the same names:
- Named front-runner: Eli Lilly — the only reported bidder; buying its way into immunology/IBD.
- Best strategic fit: AbbVie and Takeda — AbbVie owns the IBD market (Skyrizi/Rinvoq), Takeda owns Entyvio — but both are the most balance-sheet-constrained of the group.
- Best-funded credible buyers: J&J, Roche, Merck — all with IBD franchises or proven appetite (Roche’s $7.1bn Telavant/TL1A deal, Merck’s Prometheus) and ample capacity; Sanofi a less-obvious possible.
- The outsider: AstraZeneca — can clearly afford it (a $20bn deal takes it to ~2.2x net debt/EBITDA, within its rating) but has no IBD franchise; it would be gate-crashing, not defending turf.
The price tag has moved up, not down.
The €15bn/$17.5bn January number now looks like a floor for three compounding reasons: obefazimod’s Phase 3 maintenance data landed positive; the mid-year cancer-signal scare (stock -43% in early June) was largely walked back by end-June safety data (+36%); and — critically — Abivax just raised ~$920M to fund a solo US launch with runway to ~2029. That raise does two things to any bid: it adds cash to the equity bridge, and it removes the distressed-seller dynamic entirely. A buyer now has to pay a control premium over a company that has credibly said it doesn’t need one. Net effect: the realistic take-out has drifted from ~$17.5bn toward $20bn+.
Why the premium holds — a quick scarcity check (immunology only).
What makes obefazimod expensive is a rare combination: genuinely first-in-class mechanism (oral miR-124 enhancer), Phase 3 de-risked, in a market as big as UC + Crohn’s (IBD heading for ~$27–31bn by 2030). The right precedents are the recent novel-mechanism IBD takeouts, not oncology:
- Merck / Prometheus — ~$10.8bn (2023) for tulisokibart, an anti-TL1A antibody for UC/Crohn’s.
- Roche / Telavant (Roivant) — $7.1bn (2023) for RVT-3101, also anti-TL1A for IBD.
Those two set the going rate for a de-risked, new-mechanism IBD asset at roughly $7–11bn — and both were injectable antibodies still short of full Phase 3. Abivax, at a rumored ~$17.5bn-and-rising, is being marked above that band, consistent with obefazimod being (a) oral rather than injectable and (b) further along. The TL1A comps don’t undercut the price — they frame why it’s higher.
Scanning for still-independent immunology assets with a comparable “novel MoA + late-stage + large TAM” profile, there aren’t many, and each is an imperfect match:
- MoonLake (sonelokimab) — trivalent Nanobody (IL-17A/F), Phase 3 in hidradenitis suppurativa/PsA; novel format, but IL-17 is an established target and HS is a smaller market than IBD.
- Vera Therapeutics (atacicept) — dual APRIL/BAFF inhibitor, Phase 3 in IgA nephropathy; differentiated mechanism but a smaller TAM.
- Immunovant (IMVT-1402) — anti-FcRn across autoimmune indications; big aggregate TAM, but the FcRn class was already opened by argenx, so not first-in-class.
Bottom line: within immunology specifically, first-in-class + Phase 3 + IBD-scale TAM is genuinely scarce. The market has been paying $7–11bn for novel-target IBD antibodies (TL1A); Abivax pairs a novel mechanism with an oral profile in the same disease, which is exactly why its number sits above the precedents — and why any buyer, AZN included, has to stretch.
Full buyer-by-buyer ratings are in the attached scorecard (Abivax_Buyer_Scorecard.docx). Happy to firm up the exact net-debt/EBITDA per name before this goes further.
Best,
Laurent
